CD8A and COVID-19: Together, these data suggest an ongoing CD8 T‐cell response in COVID‐19 patients, with expansion of the potent Tc1/Tc17 TEM subset; however, the comparative weakness of the response and its failure to predict disease severity argue against systemic CD8 T‐cell responses being a pathogenic driver.